MONDAY, AUGUST 17

Keynote Address

James P. Allison, University of Texas MD Anderson Cancer Center, USA

Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms

Mechanisms of Action I

*Ira Mellman*, Genentech, Inc., USA

Mechanistic Basis of Cancer Immunotherapy

*Kelli Connolly*, Yale University, USA

Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells

AHyun Choi, Novartis Institutes for BioMedical Research, USA

Short Talk: Loss of EMC Inhibits Tumor Growth through Enhanced Adaptive Immune Response

Mechanisms of Action II

Jane Olario, Peter MacCallum Cancer Centre, Australia

Identifying New Targets for Cancer Immunotherapy

Vandana Kalia, University of Washington and Seattle Children’s Research Institute, USA

Short Talk: PD-1 Signals are Critical for Maintenance of CD8 T Cell Memory

Katie Campbell, University of California, Los Angeles, USA

Short Talk: Integrating DNA and RNA Sequencing Analysis to Describe Somatic Alterations and Expression in the HLA Gene Loci

Stephen Mok, MD Anderson Cancer Center, USA

Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment

Mechanisms of Response I

*Siwen Hu-Lieskovski*, Huntsman Cancer Institute, USA

Clinical Testing Strategies against Heterogeneous Mechanisms of Immune Resistance

Antoni Ribas, University of California, Los Angeles, USA

Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy

Chang Liu, University of Pittsburgh, USA

Short Talk: Neuropilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity

Mechanisms of Response II

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA

From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

*Yuxuan Miao*, Rockefeller University, USA

Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells

Shira Tabachnick-Cherny, University of Washington, USA

Short Talk: Characterization of Myeloid Cells Subsets in the Tumor Microenvironment of Merkel Cell Carcinoma

Zoila Areli Lopez Bujanda, Johns Hopkins University, USA

Short Talk: ADT-Mediated Intra-Tumoral Myeloid Infiltration Promotes Resistance to Immune Checkpoint Blockade in Prostate Cancer

Poster Session

TUESDAY, AUGUST 18

Therapeutic Play I

Yvonne Y. Chen, University of California, Los Angeles, USA

Engineering Next-Generation CAR-T Cell Therapy for Cancer

*Juan C. Jaen*, Arcus Biosciences, Inc., USA

Clinical Applications of Adenosine Pathway Inhibitors

Coralie Backlund, Massachusetts Institute of Technology, USA

Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigenic Peptide Vaccines

Maija Hollmén, University of Turku, Finland

Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours

Yingxiao Wang, University of California, San Diego, USA

Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy

Therapeutic Play II

*Evan Scott*, Northwestern University, USA

Engineered Nanobiomaterials for Cancer Immunotherapy

E. John Wherry, University of Pennsylvania, USA

Epigenetic Features of Exhausted Antitumor T Cells

Buvana Ravishankar, Rapt Therapeutics, Inc., USA

Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response

Anthony K. Park, City of Hope, USA

Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors

Patrick A. Ott, Dana-Farber Cancer Institute, USA

Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma

Meet-the-Editors Roundtable

Alessandra Fornarelli, Frontiers, Switzerland

Paloma Portela Torres, SAGE Publications Ltd, UK

Lise Roth, European Molecular Biology Organization, Germany

Genomics of Cancer I

*Priti Hegde*, Foundation Medicine, USA

Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types

Eliezer M. Van Allen, Dana-Farber Cancer Institute, USA

Tumor Genomics and Selective Response to Cancer Immunotherapy
**Nadine A. Defranoux**, Parker Institute for Cancer Immunotherapy, USA  
*Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor nEoantigen SeLection Alliance (TESLA)*

**Gloria Bora Kim**, University of Pennsylvania, USA  
*Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy*

**Genomics of Cancer II**

**Elaine R. Mardis**, Nationwide Children's Hospital, USA  
*Immunogenomics and the TME in Pediatric CNS Cancers*

**Thomas D. Wu**, Genentech, Inc., USA  
*Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy*

**Debattama Sen**, Harvard Medical School, USA  
*Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control*

**WEDNESDAY, AUGUST 19**

**Single Cell I**

**James R. Heath**, Institute for Systems Biology, USA  
*Single Cell Approaches to Analyzing Antitumor Responses*

*Ansuman Satpathy*, Stanford University School of Medicine, USA  
*Single-Cell Genomics in Cancer Immunotherapy*

**Christine Carine Moussion**, Genentech, Inc., USA  
*Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model*

**James C. Lee**, University of California, San Francisco, USA  
*Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy*

**Single Cell II**

*Sohail F. Tavazoie*, Rockefeller University, USA  
*Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy*

**Theodore Roth**, University of California, San Francisco, USA  
*Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting*

**Amanda Oliver**, Peter MacCallum Cancer Centre, Australia  
*Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy*